Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that leads to cognitive and functional decline and primarily affects the elderly population. Metabolic alterations, particularly in the amino acid and fatty acid pathways, are increasingly being recognized in AD. However, the role of sex in these metabolic changes remains insufficiently understood, despite evidence suggesting that AD may manifest more strongly in females. This study investigated sex-specific metabolic patterns in AD by analyzing routine and non-routine hematological tests, including amino acids and fatty acid profiles. The results showed that certain metabolites such as citrulline and alanine were frequently altered in patients with AD. Notably, docosahexaenoic acid, dihomo-gamma-linolenic acid, and gamma-linolenic acid levels were exclusively elevated in female patients. Additionally, females exhibited significantly lower Aβ42 and higher gamma-linolenic acid levels than males, with the trend becoming more pronounced during the early stages of the disease. Despite these differences, most metabolic markers did not show significant sex-based variation. These findings suggest that while some sex-specific metabolic differences exist in AD, a larger cohort is needed to confirm these patterns and fully understand the influence of sex on AD-related metabolic changes.
MasurkarAVMarshKMorganB, et al.
Factors affecting resilience and prevention of Alzheimer’s disease and related dementias. Ann Neurol2024;
96: 633–649.
2.
FrankBWalshMHurleyL, et al.
Cognition mediates the association between cerebrospinal fluid biomarkers of amyloid and P-Tau and neuropsychiatric symptoms. J Alzheimers Dis2024;
100: 1055–1073.
3.
NielsenJEAndreassenTGotfredsenCH, et al.
Serum metabolic signatures for Alzheimer’s disease reveal alterations in amino acid composition: a validation study. Metabolomics2024;
20: 12.
4.
Arenaza-UrquijoEMBoyleRCasalettoK, et al.
Sex and gender differences in cognitive resilience to aging and Alzheimer’s disease. Alzheimers Dement2024;
20: 5695–5719.
5.
Rosende-RocaMGarcía-GutiérrezFCantero-FortizY, et al.
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit. Alzheimers Res Ther2025;
17: 27.
6.
KimOYSongJ.Important roles of linoleic acid and α-linolenic acid in regulating cognitive impairment and neuropsychiatric issues in metabolic-related dementia. Life Sci2024;
337: 122356.
7.
McKhannGMKnopmanDSChertkowH, et al.
The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011;
7: 263–269.
8.
AlbertMSDeKoskySTDicksonD, et al.
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011;
7: 270–279.
9.
AlmeidaOPAlmeidaSA.Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriat Psychiatry1999;
14: 858–865.
10.
LiuLGracelyEJZhaoX, et al.
Association of multiple metabolic and cardiovascular markers with the risk of cognitive decline and mortality in adults with Alzheimer’s disease and AD-related dementia or cognitive decline: a prospective cohort study. Front Aging Neurosci2024;
16: 1361772.
11.
AngiolilloALecceseDCiccotelliS, et al.
Effects of nordic walking in Alzheimer’s disease: a single-blind randomized controlled clinical trial. Heliyon2023;
9: e15865.
12.
SahRPVidyaCSPereiraP, et al.
Elevated homocysteine level and brain atrophy changes as markers to screen the Alzheimer disease: Case series. Ann Geriatr Med Res2024;
28: 116–120.
13.
ZhangQWuCTanX, et al.
Homocysteine facilitates the formation of carotid atherosclerotic plaque through inflammatory and noninflammatory mechanisms. Metab Syndr Relat Disord2024;
22: 365–371.
14.
CollaboratorsGDF.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health2022;
7: e105–e125.
15.
VestRSPikeCJ.Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav2013;
63: 301–307.
16.
CañabatePMartínezGRosende-RocaM, et al.
Social representation of dementia: an analysis of 5,792 consecutive cases evaluated in a memory clinic. J Alzheimers Dis2017;
58: 1099–1108.
17.
FerrettiMTSantuccione ChadhaA.The missing X factor in Alzheimer disease. Nat Rev Neurol2021;
17: 727–728.
18.
Lopez-LeeCTorresERSCarlingG, et al.
Mechanisms of sex differences in Alzheimer’s disease. Neuron2024;
112: 1208–1221.
19.
ChuangS-WChenC-WLeeM-C, et al.
Gender-specification lifestyle factors associated with mild cognitive impairment among young-old adults in Taiwan. Aging (Albany NY)2024;
16: 13662–13675.
20.
DoeckeJDPérez-GrijalbaVFandosN, et al.
Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Total Aβ. Neurology2020;
94: e1580–e1591.
21.
WangY-RWangQ-HZhangT, et al.
Associations between hepatic functions and plasma amyloid-beta levels – implications for the capacity of liver in peripheral amyloid-beta clearance. Mol Neurobiol2017;
54: 2338–2344.
22.
SwaminathanSKAhlschwedeKMSarmaV, et al.
Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab2018;
38: 904–918.
23.
BellaverBPuig-PijoanAFerrari-SouzaJP, et al.
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. Alzheimers Dement2023;
19: 3815–3825.
24.
Parodi-RullánRGhisoJCabreraE, et al.
Alzheimer’s amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood-brain barrier integrity, and angiogenesis. Aging Cell2020;
19: e13258.
25.
SakataniK.Relationship between dementia and systemic metabolic disorders. Adv Exp Med Biol2024;
1463: 263–269.
26.
TsoyAUmbayevBKassenovaA, et al.
Pathology of amyloid-β (Aβ) peptide peripheral clearance in Alzheimer’s disease. Int J Mol Sci2024;
25.
27.
MaioliSLeanderKNilssonP, et al.
Estrogen receptors and the aging brain. Essays Biochem2021;
65: 913–925.
28.
PourhadiN, MÃRchLSHolmEA, et al.
Vaginal estrogen and association with dementia: a nationwide population-based study. Alzheimers Dement2022;
18: 625–634.
29.
RadaghdamSKaramadVNourazarianA, et al.
Molecular mechanisms of sex hormones in the development and progression of Alzheimer’s disease. Neurosci Lett2021;
764: 136221.
30.
SumienNCunninghamJTDavisDL, et al.
Neurodegenerative disease: roles for sex, hormones, and oxidative stress. Endocrinology2021;
162.
31.
CalsolaroVBottariMCoppiniG, et al.
Endocrine dysfunction and cognitive impairment. Minerva Endocrinol (Torino)2021;
46: 335–349.
32.
BagitAHaywardGCMacPhersonREK.Exercise and estrogen: common pathways in Alzheimer’s disease pathology. Am J Physiol Endocrinol Metab2021;
321: E164–E168.
33.
ChengYJLinCHLaneHY.From menopause to neurodegeneration – molecular basis and potential therapy. Int J Mol Sci2021;
22.
34.
JameieSBPirastehANaseriA, et al.
β-amyloid formation, memory, and learning decline following long-term ovariectomy and its inhibition by systemic administration of apigenin and β-estradiol. Basic Clin Neurosci2021;
12: 383–394.
35.
AgcaCKlakotskaiaDStopaEG, et al.
Ovariectomy influences cognition and markers of Alzheimer’s disease. J Alzheimers Dis2020;
73: 529–541.
36.
Vesga-JiménezDJMartinCBarretoGE, et al.
Fatty acids: an insight into the pathogenesis of neurodegenerative diseases and therapeutic potential. Int J Mol Sci2022;
23.
37.
CaldwellJZKKinneyJWRitterA, et al.
Inflammatory cytokine levels implicated in Alzheimer’s disease moderate the effects of sex on verbal memory performance. Brain Behav Immun2021;
95: 27–35.
38.
CorsoGCristofanoASapereN, et al.
Serum amino acid profiles in normal subjects and in patients with or at risk of Alzheimer dementia. Dement Geriatr Cogn Dis Extra2017;
7: 143–159.
39.
MukherjeeSPerezKADuboisC, et al.
Citrullination of amyloid-β peptides in Alzheimer’s disease. ACS Chem Neurosci2021;
12: 3719–3732.
40.
ZhaoDGaoYChenY, et al.
L-Citrulline ameliorates iron metabolism and mitochondrial quality control via activating AMPK pathway in intestine and improves microbiota in mice with iron overload. Mol Nutr Food Res2024;
68: e2300723.
41.
YuXQian-QianLCongY, et al.
Reduction of essential amino acid levels and sex-specific alterations in serum amino acid concentration profiles in children with autism spectrum disorder. Psychiatry Res2021;
297: 113675.
42.
WijnandsKACastermansTMHommenMP, et al.
Arginine and citrulline and the immune response in sepsis. Nutrients2015;
7: 1426–1463.
43.
LiuPFleeteMSJingY, et al.
Altered arginine metabolism in Alzheimer’s disease brains. Neurobiol Aging2014;
35: 1992–2003.
44.
AllertonTDStampleyJELiZ, et al.
Nitric oxide donors rescue metabolic and mitochondrial dysfunction in obese Alzheimer’s model. Sci Rep2024;
14: 26118.
45.
GriffinJWBradshawPC.Amino acid catabolism in Alzheimer’s disease brain: Friend or foe?Oxid Med Cell Longev2017;
2017: 5472792.
46.
LuYPikeJRChenJ, et al.
Changes in Alzheimer disease blood biomarkers and associations with incident All-Cause dementia. JAMA2024;
332: 1258–1269.
47.
HataJOharaTKatakuraY, et al.
Association between serum β-alanine and risk of dementia. Am J Epidemiol2019;
188: 1637–1645.
48.
NhoKKueider-PaisleyAAhmadS, et al.
Association of altered liver enzymes with Alzheimer disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers. JAMA Netw Open2019;
2: e197978.
49.
LinCHYangHTLaneHY.D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer’s disease or mild cognitive impairment. Pharmacol Biochem Behav2019;
185: 172760.
50.
Di CostanzoAParisDMelckD, et al.
Blood biomarkers indicate that the preclinical stages of Alzheimer’s disease present overlapping molecular features. Sci Rep2020;
10: 15612.
51.
NhoKKueider-PaisleyAMahmoudianDehkordiS, et al.
Altered bile acid profile in mild cognitive impairment and Alzheimer’s disease: relationship to neuroimaging and CSF biomarkers. Alzheimers Dement2019;
15: 232–244.
52.
VarmaVROommenAMVarmaS, et al.
Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med2018;
15: e1002482.
53.
KülzowNWitteAVKertiL, et al.
Impact of omega-3 fatty acid supplementation on memory functions in healthy older adults. J Alzheimers Dis2016;
51: 713–725.
54.
LinT-JChengK-CWuL-Y, et al.
Potential of cellular therapy for ALS: current strategies and future prospects. Front Cell Dev Biol2023;
11: 1292681.
55.
SoininenHSolomonAVisserPJ, LipiDiDiet clinical study groupet al.
36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement2021;
17: 29–40.
56.
WuSDingYWuF, et al.
Omega-3 fatty acids intake and risks of dementia and Alzheimer’s disease: a meta-analysis. Neurosci Biobehav Rev2015;
48: 1–9.
57.
ZhuRZChenMQZhangZW, et al.
Dietary fatty acids and risk for Alzheimer’s disease, dementia, and mild cognitive impairment: a prospective cohort meta-analysis. Nutrition2021;
90: 111355.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
